Iradimed Corp (NASDAQ:IRMD) VP Sells $41,840.00 in Stock

Share on StockTwits

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 2,000 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $20.92, for a total value of $41,840.00. Following the sale, the vice president now owns 2,368 shares in the company, valued at $49,538.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Brent Johnson also recently made the following trade(s):

  • On Wednesday, August 21st, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.62, for a total value of $20,620.00.
  • On Monday, August 19th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.21, for a total value of $21,210.00.
  • On Wednesday, August 14th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.10, for a total value of $21,100.00.
  • On Monday, August 12th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.27, for a total value of $21,270.00.
  • On Friday, August 9th, Brent Johnson sold 2,400 shares of Iradimed stock. The stock was sold at an average price of $21.81, for a total value of $52,344.00.
  • On Monday, August 5th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $21.94, for a total value of $65,820.00.
  • On Wednesday, August 7th, Brent Johnson sold 7,000 shares of Iradimed stock. The stock was sold at an average price of $21.93, for a total value of $153,510.00.
  • On Friday, August 2nd, Brent Johnson sold 5,000 shares of Iradimed stock. The stock was sold at an average price of $22.83, for a total value of $114,150.00.
  • On Wednesday, July 31st, Brent Johnson sold 8,000 shares of Iradimed stock. The stock was sold at an average price of $22.68, for a total value of $181,440.00.
  • On Monday, July 1st, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.46, for a total value of $20,460.00.

Shares of IRMD stock opened at $20.71 on Thursday. The business’s 50 day simple moving average is $20.08 and its 200 day simple moving average is $23.51. Iradimed Corp has a one year low of $16.68 and a one year high of $38.78. The stock has a market capitalization of $238.65 million, a PE ratio of 48.16 and a beta of 1.65. The company has a debt-to-equity ratio of 0.06, a current ratio of 10.29 and a quick ratio of 9.39.

A number of hedge funds have recently made changes to their positions in IRMD. Atria Investments LLC bought a new position in shares of Iradimed during the 2nd quarter worth approximately $49,696,000. BlackRock Inc. raised its position in shares of Iradimed by 14.4% during the second quarter. BlackRock Inc. now owns 390,592 shares of the medical equipment provider’s stock worth $7,988,000 after purchasing an additional 49,042 shares during the period. Renaissance Technologies LLC raised its position in shares of Iradimed by 5.0% during the second quarter. Renaissance Technologies LLC now owns 363,400 shares of the medical equipment provider’s stock worth $7,432,000 after purchasing an additional 17,200 shares during the period. Vanguard Group Inc. raised its position in shares of Iradimed by 2.5% during the second quarter. Vanguard Group Inc. now owns 276,203 shares of the medical equipment provider’s stock worth $5,649,000 after purchasing an additional 6,658 shares during the period. Finally, RK Capital Management LLC raised its position in shares of Iradimed by 49.1% during the second quarter. RK Capital Management LLC now owns 193,574 shares of the medical equipment provider’s stock worth $3,959,000 after purchasing an additional 63,713 shares during the period. Institutional investors and hedge funds own 30.22% of the company’s stock.

IRMD has been the topic of several analyst reports. Zacks Investment Research cut Iradimed from a “buy” rating to a “hold” rating in a report on Wednesday, July 3rd. ValuEngine upgraded Iradimed from a “sell” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, BidaskClub cut Iradimed from a “buy” rating to a “hold” rating in a report on Thursday, May 9th. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Iradimed has a consensus rating of “Hold” and an average target price of $31.50.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Story: Special Dividends

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pioneer Energy Services  Lowered to Sell at Zacks Investment Research
Pioneer Energy Services Lowered to Sell at Zacks Investment Research
Nice  Downgraded by BidaskClub
Nice Downgraded by BidaskClub
Redfin  Lifted to Buy at BidaskClub
Redfin Lifted to Buy at BidaskClub
SS&C Technologies  Upgraded by BidaskClub to Strong-Buy
SS&C Technologies Upgraded by BidaskClub to Strong-Buy
Svb Leerink Upgrades ACADIA Pharmaceuticals  to “Outperform”
Svb Leerink Upgrades ACADIA Pharmaceuticals to “Outperform”
Broadcom  Downgraded to “Hold” at Loop Capital
Broadcom Downgraded to “Hold” at Loop Capital


 
© 2006-2019 Zolmax.